229 related articles for article (PubMed ID: 16878453)
1. [Pathogen inactivation in labile blood products: transfusion safety and economic impact].
Cazenave JP
Bull Acad Natl Med; 2006 Jan; 190(1):169-85; discussion 186-8. PubMed ID: 16878453
[TBL] [Abstract][Full Text] [Related]
2. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.
Corash L
Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276
[TBL] [Abstract][Full Text] [Related]
3. Pathogen-reduction systems for blood components: the current position and future trends.
Seghatchian J; de Sousa G
Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168
[TBL] [Abstract][Full Text] [Related]
4. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
Seghatchian J; Hervig T; Putter JS
Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
[TBL] [Abstract][Full Text] [Related]
5. Pathogen reduction of blood components.
Solheim BG
Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
[TBL] [Abstract][Full Text] [Related]
6. The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections.
Roback JD; Conlan M; Drew WL; Ljungman P; Nichols WG; Preiksaitis JK
Transfus Med Rev; 2006 Jan; 20(1):45-56. PubMed ID: 16373187
[TBL] [Abstract][Full Text] [Related]
7. [Pathogen inactivation in platelet concentrates: the French experience].
Cazenave JP
Transfus Clin Biol; 2011 Aug; 18(4):478-84. PubMed ID: 21719338
[TBL] [Abstract][Full Text] [Related]
8. [Photochemical inactivation of pathogens in platelets and plasma: five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety].
Cazenave JP
Transfus Clin Biol; 2011 Apr; 18(2):53-61. PubMed ID: 21474358
[TBL] [Abstract][Full Text] [Related]
9. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.
Osselaer JC; Doyen C; Defoin L; Debry C; Goffaux M; Messe N; Van Hooydonk M; Bosly A; Lin JS; Lin L; Corash L
Transfusion; 2009 Jul; 49(7):1412-22. PubMed ID: 19389022
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates.
Corash L
Vox Sang; 2000; 78 Suppl 2():205-10. PubMed ID: 10938954
[TBL] [Abstract][Full Text] [Related]
11. Update on pathogen reduction technology for therapeutic plasma: an overview.
Solheim BG; Seghatchian J
Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
[TBL] [Abstract][Full Text] [Related]
12. [Towards bacterial detection in labile blood products].
Morel P
Transfus Clin Biol; 2005 Jun; 12(2):215-20. PubMed ID: 15894499
[TBL] [Abstract][Full Text] [Related]
13. Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats.
Ciaravino V; Hanover J; Lin L; Sullivan T; Corash L
Transfusion; 2009 May; 49(5):985-94. PubMed ID: 19175545
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates.
Corash L
Dev Biol (Basel); 2000; 102():115-23. PubMed ID: 10794098
[TBL] [Abstract][Full Text] [Related]
15. Update on the use of pathogen-reduced human plasma and platelet concentrates.
Seltsam A; Müller TH
Br J Haematol; 2013 Aug; 162(4):442-54. PubMed ID: 23710899
[TBL] [Abstract][Full Text] [Related]
16. [Techniques of preparation and indications of labile blood products].
Clément S
Transfus Clin Biol; 2011 Apr; 18(2):250-61. PubMed ID: 21474355
[TBL] [Abstract][Full Text] [Related]
17. [Indications for labile blood products].
Jeanne M; Rasonglès P
Rev Prat; 2001 Jun; 51(12):1318-27. PubMed ID: 11503505
[TBL] [Abstract][Full Text] [Related]
18. Progress in improving the pathogen safety of red cell concentrates.
Chapman J
Vox Sang; 2000; 78 Suppl 2():203-4. PubMed ID: 10938953
[TBL] [Abstract][Full Text] [Related]
19. Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components.
Grellier P; Benach J; Labaied M; Charneau S; Gil H; Monsalve G; Alfonso R; Sawyer L; Lin L; Steiert M; Dupuis K
Transfusion; 2008 Aug; 48(8):1676-84. PubMed ID: 18503613
[TBL] [Abstract][Full Text] [Related]
20. Transfusion medicine and safety.
Dodd R; Kurt Roth W; Ashford P; Dax EM; Vyas G
Biologicals; 2009 Apr; 37(2):62-70. PubMed ID: 19230706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
